[PDF] Top 20 Vorinostat in solid and hematologic malignancies
Has 10000 "Vorinostat in solid and hematologic malignancies" found on our website. Below are the top 20 most common "Vorinostat in solid and hematologic malignancies".
Vorinostat in solid and hematologic malignancies
... to vorinostat for the treatment of cutaneous manifestations of cutaneous T- cell lymphoma (CTCL) in patients with progressive, per- sistent or recurrent disease on or following two systemic therapies ...of ... See full document
11
Immunotherapy in hematologic malignancies: past, present, and future
... in hematologic malignancies has been the development and refinement of CAR T cell therapy, which is a field that is moving at an accelerated ...in hematologic malignancies, given several ... See full document
10
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
... regulate physiological processes within the hematopoietic compartment, could likely target genes in healthy tissues. Moreover, it has to be considered that some studies have reported an oncogenic activity of miR-29 ... See full document
25
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
... acids, vorinostat (SAHA, Zolina) was approved by the FDA in 2006 for the treatment of patients with cutaneous T-cell lymphoma (CTCL), a rare type of NHL of the ...of vorinostat showed a median duration of ... See full document
24
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
... rare solid tumor malignancies (3–6) but are present in fewer than 1% of all solid tumors ...with solid tumors harboring these fusions is striking, with an 80% overall response rate for the ... See full document
8
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
... Several Hh pathway inhibitors that target SMO have dem- onstrated single-agent efficacy in patients with ligand- independent tumors [101-105], including vismodegib, which was approved by the FDA in 2012 for the treatment ... See full document
12
The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation
... GRN163L (Imetelstat) is the most promising oligonucleo- tide possessing the ability to block telomerase by acting as a complementary sequence to hTERC. In an in vitro study, GRN163L showed effective inhibition of ... See full document
10
Laboratory Diagnosis of Infections in Cancer Patients: Challenges and Opportunities
... tologic malignancies soon after the receipt of chemotherapy treat- ...with solid tumors presented more frequently with pulmonary infections caused by Mycobacterium fortuitum and ...with hematologic ... See full document
12
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
... inhibitors, ten-eleven translocation 2 (TET2), a dioxy- genase, catalyzes DNA demethylation. TET2 mutations in AML contribute to hypermethylated DNA at en- hancers, resulting in suppression of gene expression. TET2 ... See full document
17
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
... In lymphoma, preclinical data suggest that BET inhibitors have the potential to synergize with several targeted agents presently used in practice. In one study, the BET inhibitor OTX015 was examined as a single agent, or ... See full document
11
Epidemiology of Candida kefyr in Patients with Hematologic Malignancies
... on hematologic malignancy (HM)-dedicated wards at the Johns Hopkins Hospital (A) with combined data from all study years with (empty bars) and without (solid bars) 2009 data (B) and monthly total numbers of ... See full document
8
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... CAR consisting of scFv attached to CD3ζ produces mod- est clinical results as it delivers only the first signal for T cell activation. Second-generation CARs include an add- itional co-stimulatory domain (CD28, 4-1BB, ... See full document
20
1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma
... Both solid and hematologic malignancies have been associated with this syndrome; the most frequent etiologies being multiple myeloma, lung and breast cancer ... See full document
5
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies
... on solid preclinical experience, to carefully design and carry out meaningful prospective studies using these compounds alone or in combination to improve responses, quality of life, and ultimately ... See full document
10
Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
... in hematologic malignancies such as Burkitt lymphoma and acute lymphoblastic leukemia (ALL), TLS is now observed in malignancies that had rarely been associated with TLS, including solid ... See full document
11
Successful treatment of cerebral aspergillosis: case report of a patient with T cell large granular lymphocytic leukemia (T LGL)
... on-going medication, the treatment was switched to li- posomal amphotericin B (3 mg/kg, 250 mg/d). Under this therapy, both lesions in the lungs and in the brain regressed and the patient’s clinical status bettered. Be- ... See full document
6
Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies
... Since Denning et al. reported the relationship between azole resistance and poor survival rate in a neutropenic murine model in 1997, azole resistance has been observed to be increasing in clinical A. fumigatus isolates ... See full document
13
Identification of Candida spp. isolated from oral mucosa in patients with leukemias and lymphomas in Iran
... Materials and Methods: In this cross sectional study, 50 clinical samples were collected from the mouth of patients with hematological malignancies undergoing chemotherapy from the oncology units of teaching ... See full document
6
Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature
... relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitor- ing protocols and technical aspects of ...hematological malignancies and emphasizes their therapeutic or ... See full document
11
Evaluation of enzyme immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients
... albicans cytoplasmic protein antigen enzyme immunoassay CACP antigen EIA in neutropenic patients with underlying hematologic malignancies, comparing microbiologic diagnosis, surveillance[r] ... See full document
11
Related subjects